Table 1 Baseline characteristics of 252 patients.
From: Serum ferritin predicted prognosis in patients with nasopharyngeal carcinoma
Characteristics | No. of cases | % |
|---|---|---|
Gender | ||
Male | 175 | 69.4 |
Female | 77 | 30.6 |
Age (years) | ||
≤ 45 | 95 | 37.7 |
> 45 | 157 | 62.3 |
Pathology (WHO 2022) | ||
Keratinizing squamous cell carcinoma | 2 | 0.8 |
Non-keratinizing carcinoma | 250 | 99.2 |
Basaloid squamous cell carcinoma | 0 | 0.0 |
T stage (the 8th AJCC) | ||
1 | 22 | 8.7 |
2 | 103 | 40.9 |
3 | 85 | 33.7 |
4 | 42 | 16.7 |
N stage (the 8th AJCC) | ||
0 | 9 | 3.6 |
1 | 64 | 25.4 |
2 | 126 | 50.0 |
3 | 53 | 21.0 |
Clinical TNM-stage (the 8th AJCC) | ||
I | 3 | 1.2 |
II | 28 | 11.1 |
III | 132 | 52.4 |
IVa | 89 | 35.3 |
IMRT prescribed dose | ||
GTVnx | 68–71.04 Gy/30–32 F | |
GTVnd | 64–68 Gy/30–32 F | |
Cycles of chemotherapy | ||
< 4 | 187 | 74.2 |
≥ 4 | 65 | 25.8 |
Hb (g/L) | ||
< 120 | 27 | 10.7 |
≥ 120 | 225 | 89.3 |
Serum ferritin (ng/mL) | ||
Low level group: 3.09–81.64 | 84 | 33.3 |
Medium level group: 81.73–164.00 | 84 | 33.3 |
High level group: 164.92–534.16 | 84 | 33.3 |
